

## **C-Path Selects Aridhia to Support Rare Disease Cures Accelerator-Data and Analytics Platform**



**TUCSON, Ariz., December 3, 2020** — The Critical Path Institute (C-Path) today announced it has selected Aridhia to support its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). The RDCA-DAP initiative, launched in September 2019 as a collaborative project between C-Path and the National Organization for Rare Disorders® (NORD), will provide a centralized and standardized infrastructure to accelerate and optimize the quantitative characterization of rare diseases, with the goal of accelerating therapy development. RDCA-DAP is designed to accept patient-level rare disease data from clinical trials, observational studies, real-world data, patient registries and other sources, to support the analysis and interpretation of those data.

Based in Scotland, Aridhia encompasses a multidisciplinary team of data scientists, information governance specialists, computer scientists, software developers and health care experts who are uniquely skilled to give researchers and innovators the ability to discover and understand data through dataset searching, classification and efficient metadata browsing capabilities. Aridhia will work closely with C-Path's Data Collaboration Center (DCC) team of top-tier technical, scientific and project management experts to build a neutral, precompetitive data collaboration environment to support advanced research efforts in rare diseases.

“We look forward to working with Aridhia on this exciting collaboration,” said C-Path Executive Director of Data Science Amanda Borens, MS. “RDCA-DAP is an important resource for the entire rare disease community. Using Aridhia technology, RDCA-DAP will help the community come together and share data and knowledge that will revolutionize the development of therapies for rare diseases.”

Aridhia was chosen by C-Path based on its unparalleled expertise in providing secure cloud-enabled digital research environments for biomedical, precision medicine and health care researchers. Coupled with the fact that Aridhia has been on the forefront of the fair, lawful and transparent handling of personal data — prior to the implementation of the EU's General Data Protection Regulations (GDPR) — and have continued to be an industry leader in the strict adherence to GDPR standards, Aridhia was the stand-out choice to assist with the development of the RDCA-DAP.

“We're delighted to be working with colleagues at C-Path on such an important area of biomedical research,” said Aridhia CEO David Sibbald. “We know that improving therapy development for rare disease requires significant data discovery and data access, while preserving the governance requirements of individual data contributors. Our collaboration will help the rare disease scientific community gain access to richer, more comprehensive datasets to accelerate rare disease therapy development.”

RDCA-DAP already includes integrated rare disease data from a number of different sources — including those within NORD’s IAMRARE™ registry platform — and building in advanced analytics capabilities will allow efficient and effective interrogation of that data to generate solutions for clinical trial design and regulatory review.

Groups interested in contributing data to the effort, collaborating on rare disease research or using the platform for their own research may visit [c-path.org/rdca-dap](https://c-path.org/rdca-dap) or email [rdcadap@c-path.org](mailto:rdcadap@c-path.org) for more information. The platform is open to accept data immediately and the user interface and analytics will be available in early 2021, with additional analytics tools being developed concurrently.

*Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 69% funded by FDA/HHS, totaling \$19,471,171, and 31% percent funded by non-government source(s), totaling \$8,612,313. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.*

---



#### **About Critical Path Institute**

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path US is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit [c-path.org](https://c-path.org) and [c-path.eu](https://c-path.eu).



#### **About Aridhia**

Aridhia is a health data science company founded in 2008 and based in Glasgow’s Queen Elizabeth University hospital and central Edinburgh. Aridhia provides a cloud based digital research platform enabling both the discovery and analysis of data to take place in a trusted, secure environment at scale. Our multidisciplinary team of data scientists, information governance specialists, computer scientists, software developers and health care experts delivers research services across the UK and Europe, working collaboratively with the NHS, research organizations, life sciences companies, IT service providers and patients to transform clinical research into clinical practice.

**Contact:**

Kissy Black

C-Path

[kissyblack@c-path.org](mailto:kissyblack@c-path.org)